rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Hormone Therapy and Castration Resistance of Prostate Cancer
  name:
    name part: Arai, Yoichi.
    role:
      role term: editor.
    role:
      role term: edt
    role:
      role term: http://id.loc.gov/vocabulary/relators/edt
  name:
    name part: Ogawa, Osamu.
    role:
      role term: editor.
    role:
      role term: edt
    role:
      role term: http://id.loc.gov/vocabulary/relators/edt
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  origin info:
    place:
      place term: si
    date issued: 2018
    edition: 1st ed. 2018.
    issuance: monographic
  language:
    language term: eng
  physical description:
    form: electronic
    form: electronic resource
    reformatting quality: access
    form: remote
    extent: VIII, 433 p. 65 illus., 34 illus. in color. online resource.
  abstract: This comprehensive reference expounds the current state of hormone therapy and castration resistance of prostate cancer (PCa). Previously, the incidence of PCa in Asian countries was relatively low, but it has been increasing dramatically in recent years. Although most of the new cases are diagnosed in early stages, a significant proportion of patients receive hormone therapy for metastatic disease or for relapse after local treatment. Thus the situation has gradually changed toward earlier and longer use of hormone therapy. The malignancy finally forms castration-resistant prostate cancer (CRPC) despite the lack of testicular androgen. With advances in understanding of the molecular basis of hormone dependence and CRPC, many new androgen receptor-targeted agents have emerged. During the last decade, much evidence on hormone therapy has been accumulated in Japan. Interestingly, some of these findings are different from those reported from Western countries, suggesting ethnic variation in the outcome of hormone therapy. In the chapters of this book, expert authors provide exhaustive interpretations of the evidence recently reported from Japan and provide important Asian perspectives on hormone therapy for PCa. This work benefits not only Asian urologists but also their Western counterparts and all physicians and medical personnel who are involved in the treatment of PCa.
  table of contents: 1. Introduction -- 2. Recent trends in hormone therapy for prostate cancer in Japan -- 3. Risk assessment among patients receiving primary ADT -- 4. Patient-derived xenografts for research on hormonal therapy of prostate cancer -- 5. Impact of GnRH antagonist and LHRH agonist on the gonadal axis -- 6. Controversies on complete androgen blockade -- 7. Adrenal androgen in prostate cancer -- 8. Intermittent ADT for prostate cancer -- 9. Pognostic significance of monitoring serum testosterone in primary ADT -- 10. Ethnic variation in clinical outcomes of primary ADT for prostate cancer -- 11. ADT in combination with radical prostatectomy -- 12. ADT in combination with radiation therapy -- 13. ADT as salvage therapy after definitive treatment -- 14. ADT for clinically localised prostate cancer -- 15. Complications of ADT -- 16. Hot flash -- 17. Oseteoporosis and fracture risk -- 18. Metaboplic change -- 19. Bone scan index as a biomarker of bone metastasis -- 20. Genetic polymorphism analysis in predicting prognosis of metastatic prostate cancer -- 21. Local therapy in combination with ADT for metastatic prostate cancer -- 22. Oxidative stress and CRPC -- 23. Alternative antiandrogen therapy for CRPC -- 24. Optimization of sequential AR targeted therapy for CRPC -- 25. Enzalutamide therapy for mCRPC in Japanese men -- 26. Abiraterone acetate therapy for mCRPC in Japanese men -- 27. Role of estramustine phosphate for CRPC -- 28. Steroid therapy for CRPC -- 29. MicroRNA analysis in prostate cancer -- 30. AR splicing variant in prostate cancer -- 31. Detection of CTC in CRPC -- 32. New biomarker for CRPC: Glycobiologic perspective -- 33. Bone-tageted treatment in CRPC management -- 34. Skeletal complications in CRPC patients -- 35. Urological complications in men dying from prostate cancer -- 36. Prediction of optimal docetaxel regimen for patients with mCRPC -- 37. Intermittent chemotherapy with decetaxel for mCRPC -- 38. Chemotherapy with cabazitaxel for ｍCRPC in Japanese…
  note: edited by Yoichi Arai, Osamu Ogawa.
  subject:
    topic: Urology
  subject:
    topic: Oncology
  subject:
    topic: Urology
  subject:
    topic: Oncology
  classification: RC870-923.2
  classification: RC875-899.5
  classification: 616.6
  related item:
    title info:
      title: Springer eBooks
  identifier: 9789811070136
  identifier: https://doi.org/10.1007/978-981-10-7013-6
  record info:
    record creation date: 180511
    record change date: 20191220130313.0
    record identifier: 978-981-10-7013-6